Avatrombopag – Thrombopoietin Receptor Agonist for Thrombocytopenia
Avatrombopag is an oral, highly selective, second-generation small-molecule thrombopoietin receptor (c-Mpl) agonist engineered for the pathogenic treatment of severe thrombocytopenia of various etiologies. The mechanism of action of avatrombopag involves specific binding to the transmembrane domain of thrombopoietin receptors on the surface of hematopoietic stem cells and megakaryocytes. The drug mimics the biological activity of endogenous thrombopoietin, initiating intracellular JAK/STAT and MAPK signaling cascades. This pathway activation stimulates the targeted proliferation and differentiation of megakaryocyte progenitor cells, accelerates their maturation, and enhances the shedding of functionally active platelets, leading to a dose-dependent increase in peripheral platelet counts. A critically important clinical feature of avatrombopag is that it binds to a distinct site on the receptor and does not compete with natural thrombopoietin, providing a synergistic therapeutic effect without inducing neutralizing autoantibodies.
The clinical uniqueness of avatrombopag lies in its capacity to rapidly and predictably expand platelet counts in patients with chronic liver diseases, enabling the safe execution of scheduled invasive diagnostic and surgical interventions without requiring prophylactic donor platelet transfusions. The drug exhibits high oral bioavailability, which is significantly enhanced when co-administered with a high-fat meal. Peak plasma exposure is achieved within 5 to 6 hours. Avatrombopag possesses a prolonged elimination half-life (approximately 19 hours) and undergoes oxidative hepatic clearance mediated primarily via CYP2C9 and CYP3A4 isoenzymes. Systemic excretion of the parent compound and its metabolites is achieved predominantly through the intestines in the feces, with only a minimal fraction cleared via the kidneys in the urine.
The drug is administered orally. Initiating therapy requires mandatory baseline determination of peripheral platelet levels via a complete blood count. Regular laboratory monitoring of the hemogram is essential throughout short-term preoperative courses or long-term regimens to prevent excessive thrombocytosis and minimize systemic thromboembolic liabilities.
Indications
Avatrombopag is indicated as a systemic targeted therapy for adult patients presenting with the following conditions associated with thrombocytopenia:
- Thrombocytopenia in Chronic Liver Disease: treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo any planned invasive medical or surgical procedure.
- Immune Thrombocytopenia (ITP): treatment of persistent or chronic primary immune thrombocytopenia in adult patients who exhibit resistance or an inadequate clinical response to prior first-line interventions (such as corticosteroids, immunoglobulins, or splenectomy).
Dosage and administration
The dosing regimen of avatrombopag is individually tailored based on the clinical indication and baseline platelet counts, and strictly requires administration with food.
- Dosing for Scheduled Invasive Procedures: in chronic liver disease, dosing is stratified by baseline platelet count. For counts below 40 x 10⁹/L, the recommended dose is 60 mg (three tablets) orally once daily. For counts from 40 x 10⁹/L to under 50 x 10⁹/L, the dose is 40 mg (two tablets) orally once daily. Therapy begins 10 to 13 days prior to the procedure, continues for exactly 5 consecutive days, and the procedure should be performed 5 to 8 days after the final dose.
- Dosing for Chronic ITP: the recommended initial dose is 20 mg (one tablet) orally once daily. Subsequent titration is performed (ranging from 20 mg once weekly up to a maximum of 40 mg daily) to achieve and maintain a stable target platelet count of at least 50 x 10⁹/L to reduce bleeding risks.
- Administration Method: tablets must be swallowed whole at approximately the same time each day and must be taken with food (ideally a high-fat meal). Tablets must not be broken or crushed during handling.
- Missed Dose: if a scheduled dose is missed, the patient should take it immediately with food as soon as it is remembered. However, if the time overlaps closely with the next scheduled dose, the missed dose should be skipped; a double dose must never be taken.
- Dose Modification for Thrombocytosis: if platelet counts exceed the therapeutic target (above 400 x 10⁹/L) during ITP treatment, avatrombopag must be immediately withheld. Therapy may be resumed after counts fall below 150 x 10⁹/L, with a step-down dose reduction.
